Brickell Biotech, Inc.: directors' dealings · United States · SEC (Form 4)

About Brickell Biotech, Inc.

Brickell Biotech, Inc. is a United States biopharmaceutical company that was historically focused on dermatology and inflammatory diseases, with a profile that is highly familiar to investors who follow small-cap clinical-stage names listed in the U.S. market. The company traces its operating origins to a private entity that began activities in September 2009, and it became the public company Brickell Biotech, Inc. through a reverse-merger recapitalization completed on August 31, 2019. At that point, the business previously conducted by Brickell became the business of the listed company, and the corporate headquarters were in Boulder, Colorado, United States. SEC filings and company disclosures identified the stock as listed on Nasdaq (NASDAQ: BBI) during the period when Brickell was operating under that name. ([sec.gov](https://www.sec.gov/Archives/edgar/data/819050/000081905021000029/bbi-20201231.htm?utm_source=openai)) Operationally, Brickell was best described as a clinical-stage pharmaceutical company rather than a commercial-stage drug maker. Its development strategy centered on a small number of differentiated prescription therapeutics, with the best-known asset being sofpironium bromide, a topical anticholinergic developed for primary axillary hyperhidrosis. Brickell worked with Kaken Pharmaceutical on development and commercialization in Asia, and Kaken commercialized the product in Japan under the brand ECCLOCK. The company also discussed additional research programs aimed at autoimmune, inflammatory, and other debilitating diseases, but the portfolio remained relatively concentrated and therefore more dependent on binary clinical and regulatory milestones than on a broad revenue base. ([sec.gov](https://www.sec.gov/Archives/edgar/data/819050/000081905019000006/brickell8-k.htm?utm_source=openai)) From a competitive standpoint, Brickell operated in a crowded dermatology and specialty-pharma landscape, competing against larger pharmaceutical companies, better-capitalized biotech peers, and alternative therapies across prescription, specialty, and sometimes over-the-counter channels. Its competitive edge was tied to the scientific differentiation of its lead candidate, the regulatory optionality around its pipeline, and the management team’s experience in product development and global commercialization. However, as is typical for micro- and small-cap biotechs, the investment case carried substantial execution risk, including trial outcomes, financing needs, partner dependence, and market access uncertainty. ([sec.gov](https://www.sec.gov/Archives/edgar/data/819050/000081905022000016/bbi-20211231.htm?utm_source=openai)) A major strategic turning point came in May 2022, when Brickell sold the rights to sofpironium bromide to Botanix Pharmaceuticals. The transaction included an upfront payment, reimbursement of certain development costs, and potential milestone payments, effectively monetizing the company’s lead asset. Later company filings state that all clinical and preclinical development programs were discontinued, and on September 7, 2022, the company changed its corporate name to Fresh Tracks Therapeutics, Inc. For investors reviewing insider Form 4 activity, that history matters: the legal issuer may persist through name and strategy changes, so the ticker, corporate name, and business model must be checked carefully before drawing conclusions about insider transactions. ([sec.gov](https://www.sec.gov/Archives/edgar/data/819050/000081905022000026/a202205038kex991.htm?utm_source=openai))